FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

BRADSHER NEAL C 		2. Issuer Name and Ticker or Trading Symbol

BIOTIME INC [ BTX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O BROADWOOD CAPITAL INC., 724 FIFTH AVENUE, 9TH FLOOR 		3. Date of Earliest Transaction (MM/DD/YYYY)

7/1/2019
(Street)

NEW YORK, NY 10019
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
OPTION TO PURCHASE COMMON SHARES   $1.03   7/1/2019     A      40000       7/1/2019   (1) 6/30/2029   COMMON SHARES   40000   $0   (2) 40000   D    
OPTION TO PURCHASE COMMON SHARES   $2.06                    6/30/2019   (3) 6/30/2023   COMMON SHARES   49440   (4)   49440   (4) D    
OPTION TO PURCHASE COMMON SHARES   $3.15                    7/3/2018   (3) 6/30/2022   COMMON SHARES   24720   (5)   24720   (5) D    
OPTION TO PURCHASE COMMON SHARES   $2.72                    7/3/2018   (3) 6/30/2021   COMMON SHARES   24720   (5)   24720   (5) D    
OPTION TO PURCHASE COMMON SHARES   $3.57                    7/3/2018   (3) 6/30/2020   COMMON SHARES   24720   (5)   24720   (5) D    

Explanation of Responses:
(1)  These options will vest and become exercisable on June 30, 2020, provided, that Neal C. Bradsher remains a member of the issuer's board of directors on that date.
(2)  The options were granted to Neal Bradsher by the issuer on July 1, 2019 as director compensation pursuant to resolutions from the minutes of the issuer's board of directors meeting on January 24, 2018.
(3)  These options are currently exercisable.
(4)  On November 28, 2018, the issuer distributed to its shareholders approximately 12.7 million shares of common stock of AgeX Therapeutics, Inc. ("AgeX") in the ratio of one share of AgeX common stock for every 10 common shares of the issuer owned by its shareholders (the "AgeX Distribution"). Pursuant to the AgeX Distribution, the issuer adjusted the amount of options held by its directors. In particular, the 40,000 options expiring on June 30, 2023 that were previously granted to Neal C. Bradsher were increased to 49,440 to reflect the AgeX Distribution.
(5)  Pursuant to the AgeX Distribution, (i) the 20,000 options expiring on June 30, 2022 that were previously granted to Neal C. Bradsher were increased to 24,720, (ii) the 20,000 options expiring on June 30, 2021 that were previously granted to Neal C. Bradsher were increased to 24,720, and (iii) the 20,000 options expiring on June 30, 2020 that were previously granted to Neal C. Bradsher were increased to 24,720.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
BRADSHER NEAL C
C/O BROADWOOD CAPITAL INC.
724 FIFTH AVENUE, 9TH FLOOR
NEW YORK, NY 10019 		X X


Signatures
/s/ Neal C. Bradsher 7/3/2019
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Brooklyn ImmunoTherapeut... Charts.
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Brooklyn ImmunoTherapeut... Charts.